Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

SMS Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,700,385

508 payments

Through program year 2025, SMS Clinical Research LLC is reported as receiving $4,700,385 in research payments, across 508 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,680,741 204
2024 Research $604,035 79
2023 Research $925,905 84
2022 Research $355,005 36
2021 Research $59,238 29
2020 Research $1,060,924 66
2019 Research $14,536 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,658,365 68 payments
  2. Bavarian Nordic A/S $673,160 59 payments
  3. Sanofi US Services Inc. $627,995 66 payments
  4. Genentech, Inc. $509,070 42 payments
  5. GlaxoSmithKline, LLC. $489,618 98 payments
  6. Cleerly, Inc. $344,528 37 payments
  7. Abbott Laboratories $195,862 108 payments
  8. Amgen Inc. $121,891 4 payments
  9. Allergan Inc. $37,981 13 payments
  10. F. Hoffmann-La Roche AG $23,298 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $936,565 19 payments
  2. Roche Cancer Screening Collection Study $509,070 42 payments
  3. A Phase 12 Randomized Doubleblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $506,994 22 payments
  4. Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $373,272 42 payments
  5. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $364,217 39 payments
  6. Transform $344,528 37 payments
  7. A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T $311,838 19 payments
  8. Nct05238025 $308,943 20 payments
  9. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $228,875 21 payments
  10. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Covid19 Vaccine and A Recombinant Influenza Vaccine Administered As A Single Injection in Healthy Adults 50 Years of Age Or Older $175,420 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record